Bachem Holding AG operates in the Commercial physical research sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Bachem Holding AG with three other
miscellaneous service companies in Europe:
sales of 1.82 billion Danish Kroner [US$281.23 million]
of which 100%
(1.98 billion Swedish Kronor [US$238.53 million]
of which 63%
was LabTech), and
Pharma Mar SA
based in Spain
(180.95 million Euro [US$208.46 million]
of which 62%
was Biotech Sector).
Bachem Holding AG reported sales of 236.48 million Swiss Francs (US$247.36 million)
December of 2016.
increase of 13.4%
versus 2015, when the company's sales were 208.60 million Swiss Francs.
Sales at Bachem Holding AG have increased during each of the previous five years
(and since 2011, sales have increased a total of 62%).
Sales of Active Pharmaceutical Ingredients saw an increase
19.8% in 2016, from
175.78 million Swiss Francs to 210.56 million Swiss Francs.
Not all segments of Bachem Holding AG experienced an increase in sales in 2016:
sales of Research Ingredients fell 21.0% to 25.92 million Swiss Francs.